Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532539RecruitingPhase 2
Cadonilimab with radiation for recurrent endometrial cancer
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
Jinan, ShandongAges 18–80 - NCT06540729RecruitingPhase 2
Combination treatment for ovarian clear cell cancer
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
Guanzhou, GuangdongAges 18–75 - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06529809RecruitingPhase 1/Phase 2
Accelerated brachytherapy and chemo for advanced cervical cancer
This trial tests a new way of delivering radiation therapy (brachytherapy) combined with chemotherapy for advanced cervical cancer. The goal is to see if a faster, more intense radiation schedule is safe and effective.
St Louis, MissouriAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Daphne, AlabamaAges 18 years+ - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT06476067Recruiting
Predicting early esophageal cancer return after surgery
This trial uses stored tumor tissue to try to predict if esophageal cancer will come back early after surgery. It is for people who had surgery only (no chemo or radiation) and have been followed for at least 2 years.
Nagoya, Aichi-kenAges 20 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT06443996Enrolling by invitation
Sleep, mood, and colorectal cancer recovery study
This study looks at how your sleep quality and emotional well-being before surgery might affect your recovery from colorectal cancer. By filling out questionnaires, you help doctors learn whether these factors play a role in the cancer coming back.
ShanghaiAges 18–80 - NCT06079983RecruitingPhase 3
JSKN003 vs. doctor's choice for HER2-low breast cancer
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06424626Enrolling by invitationPhase 1
Testing new drug combos for advanced mucosal melanoma
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
BeijingAges 18 years+ - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06420973RecruitingPhase 2
Testing RC48 for ovarian cancer returning after platinum treatment
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06434896Recruiting
Blood test to guide chemotherapy in stage II colon cancer
This trial is for people with stage II colon cancer who are not currently getting chemotherapy. It uses a blood test to look for tumor DNA, so doctors can decide if chemotherapy might help prevent the cancer from coming back.
's-HertogenboschAges 18 years+ - NCT04858880Recruiting
Personalized radiation for PSA rise after prostate surgery
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
JönköpingAges 18 years+ - NCT06382818Recruiting
Personalized breast radiation based on risk and side effects
This trial tests whether radiation therapy can be personalized based on your risk of the cancer coming back and your risk of side effects from radiation. Depending on those factors, you may receive a tailored radiation plan that could be more or less intense.
MontpellierAges 18 years+ - NCT06367972RecruitingPhase 2/Phase 3
Extending systemic therapy with local treatment for limited cancer growth
This trial tests whether adding local treatments like radiation or surgery to standard therapy can help control cancer that has started to grow in just a few spots. It is for people with certain advanced cancers that have 1 to 5 growing lesions that can be treated locally.
Houston, TexasAges 18 years+ - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Fountain Valley, CaliforniaAges 18 years+ - NCT06349590RecruitingPhase 1/Phase 2
Diet before colon cancer surgery to reduce recurrence
This trial tests whether a specific diet before colon cancer surgery can change the bacteria in your gut to help prevent the cancer from coming back or spreading. Patients who are eligible will follow the diet for a short time before their operation.
Chicago, IllinoisAges 18 years+ - NCT06326190RecruitingPhase 2
Study of radioactive drug for recurrent meningioma
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
InnsbruckAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.